Vik Bajaj's startup incubator at Foresite uncloaks an immunology player with a lead TYK2 inhibitor in tow
Looking at a healthcare system made more unequal by Covid-19, Foresite Capital managing director Vik Bajaj recently launched an expansive plan to launch five innovative startups to address unmet need. Just weeks after the first of those biotechs emerged from stealth, a second has now uncloaked, and it’s got immunology in its sights.
Esker Therapeutics launched Wednesday with a $70 million Series A to pursue precision immunology targets backed by Foresite Labs’ analytics engine kickstarted by Bajaj’s team, the biotech said. Foresite footed the entire round for Esker as it continues to develop its pipeline and advance its lead compound.